First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors
Elizabeth J. Davis(Vanderbilt University Medical Center), Janice M. Mehnert(NYU Langone Health), Dana B. Cardin(Vanderbilt University Medical Center), Jason A. Clark(Incyte (United States)), Prashanth Hari Dass(Churchill Hospital), Angela Orcurto(University of Lausanne), Juan Martín-Liberal(Institut d'Investigació Biomédica de Bellvitge), Rowan Miller(Queen Mary University of London), Sarah P. Blagden(Churchill Hospital), Thomas Condamine(Carisma Therapeutics (United States)), Dominik Berthold(University Hospital of Lausanne), Daniel C. Cho(NYU Langone Health), Rebecca Kristeleit(Guy's and St Thomas' NHS Foundation Trust), Kristen Spencer(Rutgers Cancer Institute), Xuejun Chen(Incyte (United States)), Jennifer Pulini(Incyte (United States)), John E. Janik(Incyte (United States)), María Vieito(Vall d'Hebron Hospital Universitari)
Cited by 93
Related Papers
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
|JAMA Oncology|2015|656
Regulation of Tumor Metastasis by Myeloid-Derived Suppressor Cells
|Annual Review of Medicine|2014|505